Skip to content

Twitter Linkedin Instagram

info@pharmaust.com+61 8 9202 6814

PharmAust (PAA)

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

Daily Archives: December 13, 2017

Phase II Dog Lymphoma Trial Confirms Monepantel Clinical Benefit

News & Announcements 2017By Richard Hopkins December 13, 2017

171211_Lymphoma Trial Result_(clean)

Recent Articles

31 January 2020, Top 20 Shareholders
January 31, 2020
28 January, Appendix 4C and Quarterly Update
January 28, 2020
$700K R&D Tax Incentive Refund.
January 14, 2020
Epichem Awarded DNDi Contract Extension
January 8, 2020

MENU

Home
About Us
Pipeline & Trials
Investor Centre
Media
Contact Us

SUBSCRIBE TO OUR NEWSLETTER

Leave this field empty if you're human:

TWITTER

PharmAustFollow

PharmAust is a clinical-stage company developing novel targeted cancer therapeutics for both humans and animals. ASX: $PAA

PharmAust @PharmAust·

Animal Healthcare Market Size Worth US$ 177.1 Billion by 2026 https://www.prnewswire.com/news-releases/animal-healthcare-market-size-worth-us-177-1-billion-by-2026--301000272.html

Reply on Twitter 1225444110309347331 Retweet on Twitter 12254441103093473311 Like on Twitter 12254441103093473313 Twitter 1225444110309347331

Copyright © 2020 Pharmaust. All rights reserved.

Website Design & Digital Marketing Perth by Total Click Solutions